Barclays initiated coverage of Envista (NVST) with an Overweight rating and $24 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target raised to $19 from $18 at Mizuho
- Envista Holdings’ Earnings Call Highlights Strong Growth
- Envista price target raised to $27 from $25 at Baird
- Envista Holdings: Strong Q3 Performance and Upward Guidance, Yet Valuation Concerns Justify Hold Rating
- Envista Holdings: Positive Growth Trends and Margin Improvements Drive Buy Rating